NEW YORK (GenomeWeb) – Veracyte reported after the close of the market on Monday that its third quarter revenues rose 34 percent year over year, as its genomic testing volume rose 23 percent during the same period.

For the three months ended Sept. 30, the South San Francisco, California-based company reported Q3 revenues of $23.5 million, up from revenues of $17.5 million a year ago and beating the average analyst estimate of $21.5 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.